End to End Connectivity Consultant Project

Consultant to identify gaps and needs among biopharmaceutical manufacturing industry members in the focus area of End-to-End Connectivity. The result will influence the Big Data Program FY27 End-to-End Connectivity project.

Industry Need

In order to build and create a holistic and interoperable data structure and management process for the industry, we need to start with data sets that are defined and formatted to industry standards. There are a few data schema standards already available for specific applications and use cases, and a number of other data-related standards currently under development. NIIMBL would like to compliment these existing and new standards and avoid developing redundant data schema solutions. In order to achieve this objective, we need to make sure that we know about all of the data schema solutions already available or under development and identify if there are any gaps with respect to the target applications and use cases defined by the NIIMBL Data Structure and Management Team.

Approach

In this capacity, the consultant will 1) receive information from NIIMBL members pertaining to the “industry needs”, 2) identify “solutions” with published evidence which address the needs, 3) analyze “need / solution pairs” using a interoperability conceptual framework to document gaps and challenges, 4) document and deliver solution, challenge, and gap findings to the Big-Data Program / Data Structure and Management Workstream within the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

Value Statement/Outcomes

This initiative maximizes ROI by eliminating the high costs of redundant development, potentially reducing engineering overhead by 20–30% and ensuring industry members leverage existing global standards rather than investing in expensive, custom-built data silos.

By resolving interoperability gaps now, our accelerated technology transfers by up to 40% and improve speed-to-market by 3–6 months through seamless, standardized data exchange across our global manufacturing network.

Ultimately, this project provides the foundational architecture required to scale high-value AI and Big Data analytics, transforming raw bioprocessing information into a streamlined enterprise asset that can drive a 15–25% increase in operational throughput.